Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

antibody (1)

    displaying 1 - 7 records in total 7
    records per page




    Screening and testing for a suitable untransfected cell line for SARS-CoV-2 studies

    Authors: Claudia Pommerenke; Ulfert Rand; Stefan Nagel; Margarete Zaborski; Vivien Hauer; Maren Kaufmann; Corinna Meyer; Sabine A. Denkmann; Peggy Riese; Kathrin Eschke; Yeonsu Kim; Zeljka Macak Safranko; Ivan-Christian Kurolt; Alemka Markotic; Linda Brunotte; Stephan Ludwig; Luka Cicin-Sain; Laura Steenpaß

    doi:10.1101/2020.07.09.195040 Date: 2020-07-09 Source: bioRxiv

    At present, the novel pandemic coronavirus SARS-CoV-2 is a major global threat to human health and hence demands united research activities at different levels. Finding appropriate cell systems for drug screening and testing molecular interactions of the virus with the host cell is mandatory for drug development and understanding the mechanisms of viral entry and replication. For this, we selected human cell lines represented in the Cancer Cell Line Encyclopedia (CCLE) based on RNA-seq data determined transcript levels of ACE2 and TMPRSS2, two membrane proteins that have been identified to aid SARS-CoV-2 entry into the host cell. mRNA and protein expression of these host factors were verified via RQ-PCR and western blot. We then tested permissiveness of these cell lines towards SARS-CoV-2 infection MESHD, cytopathic effect, and viral replication finding limited correlation between receptor expression and infectability. One of the candidate cancer cell lines, the human colon cancer HP cell line CL-14, tested positive for SARS-CoV-2 infection MESHD. Our data argue that SARS-CoV-2 in vitro infection MESHD models need careful selection and validation since ACE2/TMPRSS2 receptor expression on its own does not guarantee permissiveness to the virus. Author summaryIn the midst of the pandemic outbreak of corona-virus SARS-CoV-2 therapeutics for disease MESHD treatment are still to be tested and the virus-host-interactions are to be elucidated. Drug testing and viral studies are commonly conducted with genetically manipulated cells. In order to find a cell model system without genetic modification we screened human cell lines for two proteins known to facilitate entry of SARS-CoV-2. We confirmed and quantified permissiveness of current cell line infection MESHD models, but dismissed a number of receptor-positive cell lines that did not support viral replication. Importantly, ACE2/TMPRSS2 co-expression seems to be necessary for viral entry but is not sufficient to predict permissiveness of various cancer cell lines. Moreover, the expression of specific splice variants and the absence of missense mutations of the host factors might hint on successful infection MESHD and virus replication of the cell lines.

    The encounter of tumor and SARS-CoV-2: Pathological findings in a patient with colon cancer HP and COVID-19

    Authors: Weixiang Zhong; Jun Li; Mei Kong; Qiqi Gao; Xiaodong Teng; Tingbo Liang; Jing Zhang

    doi:10.21203/rs.3.rs-38812/v1 Date: 2020-06-29 Source: ResearchSquare

    As coronavirus disease MESHD 2019 (COVID-19) spreads worldwide, there have been few reports of infections MESHD among the cancer population, although more than six million cases have been confirmed TRANS. Here we studied a surgical specimen from a patient with colon cancer HP and COVID-19 and two tissue microarrays comprising 103 colorectal cancer and 108 enterocyte cases pathologically. The results showed that, severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) nucleocapsid antibody SERO was positively expressed in colon cancer HP tissues. Moreover, the angiotensin converting enzyme 2 (ACE2) was overexpressed in both colorectal cancer tissue microarray and tumor tissue from this patient, with a positive rate as high as 93.2%. Finally, this case of SARS-CoV-2 infection MESHD in colon cancer HP tumor microenvironment (TME) is a failure of immune homeostasis, due to the decrease in TIA + and Granzyme B+ (GrB) CD8 + T cell proportion and the increase in PD-1 + CD8 + T cell proportion. In summary, we speculate that these three factors may have contributed significantly to infection MESHD infection risk TRANS infection risk TRANS risk and severity in the patient.

    Colon Cancer HP and SARS-CoV-2: Impact of ACE2 Expression in Susceptibility to COVID-19

    Authors: Mohsen Ahmadi; Negin Saffarzadeh; Mohammad Amin Habibi; Fatemeh Hajiesmaeili

    doi:10.1101/2020.06.11.146878 Date: 2020-06-13 Source: bioRxiv

    Novel coronavirus disease MESHD (COVID-19) pandemic has become a global health emergency MESHD. Severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) interacts with angiotensin-converting enzyme 2 (ACE2) to enter the cells and infects diverse human tissues. It has been reported that a few conditions, including cancer, predispose individuals to SARS-CoV-2 infection MESHD infection and severe HP and severe form of COVID-19. These findings led us to evaluate the susceptibility of colon adenocarcinoma HP adenocarcinoma MESHD (COAD) patients to SARS-CoV-2 infection MESHD by investigation of ACE2 expression in their tumor tissues. The expression analysis revealed that both mRNA and protein levels of ACE2 had increased in colon cancer HP samples than normal group. Next, the prognosis analysis has indicated that the upregulation of ACE2 was not correlated with patient survival outcomes. Further assessment displayed the hypomethylation of the ACE2 gene promoter in COAD patients. Surprisingly, this methylation status has a strong negative correlation with ACE2 gene expression. The functional enrichment analysis of the genes that had similar expression patterns with ACE2 in colon cancer HP tissues demonstrated that they mainly enriched in Vitamin digestion and absorption, Sulfur relay system, and Fat digestion and absorption pathways. Finally, we found that ACE2 gene expression had a significant association with the immune cell infiltration levels in COAD patients. In conclusion, it has plausible that COAD patients are more likely to be infected with SARS-CoV-2 and experience severe injuries. Moreover, COVID-19 would bring unfavorable survival outcomes of patients with colon cancer HP by the way of immune cell infiltration linked process. The present study highlights the importance of preventive actions for COAD patients during the COVID-19 pandemic.

    Detection dogs as a help in the detection of COVID-19: Can the dog alert on COVID-19 positive persons by sniffing axillary sweat samples? Proof-of-concept study

    Authors: Riad Sarkis; Jean-Pierre Tourtier

    doi:10.1101/2020.06.03.132134 Date: 2020-06-05 Source: bioRxiv

    The aim of this study is to evaluate if the sweat produced by COVID-19 persons (SARS-CoV-2 PCR positive) has a different odour for trained detection dogs than the sweat produced by non COVID-19 persons. The study was conducted on 3 sites, following the same protocol procedures, and involved a total of 18 dogs. A total of 198 armpits sweat samples were obtained from different hospitals. For each involved dog, the acquisition of the specific odour of COVID-19 sweat samples required from one to four hours, with an amount of positive samples sniffing ranging from four to ten. For this proof of concept, we kept 8 dogs of the initial group (explosive detection dogs and colon cancer HP detection dogs), who performed a total of 368 trials, and will include the other dogs in our future studies as their adaptation to samples scenting takes more time.The percentages of success of the dogs to find the positive sample in a line containing several other negative samples or mocks (2 to 6) were 100p100 for 4 dogs, and respectively 83p100, 84p100, 90p100 and 94p100 for the others, all significantly different from the percentage of success that would be obtained by chance alone.We conclude that there is a very high evidence that the armpits sweat odour of COVID-19+ persons is different, and that dogs can detect a person infected by the SARS-CoV-2 virus.Competing Interest StatementThe authors have declared no competing interest.View Full Text

    Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: A structured summary of a study protocol for a randomised controlled trial.

    Authors: Abolghasem Allahyari; Hossein Rahimi; Majid Khadem-Rezaiyan; Zahra Mozaheb; Mohsen Seddigh-Shamsi; Alireza Bary; Mostafa Kamandi; Sajad Ataei Azimi; Saeed Eslami HasanbAbadi; Alireza Noferesti; Somayeh Sadat Shariatmaghani; Houshang Rafatpanah; Shohreh Khatami; Afshin Jabbar Imani; Hassan Mortazi; Mohammad Moeini Nodeh

    doi:10.21203/rs.3.pex-969/v1 Date: 2020-06-05 Source: ResearchSquare

    This is a multi-center, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. All patients over the age TRANS of 15 from 5 types of cancer, acute lymphoid and myeloid leukemias MESHD myeloid leukemias HP, non-Hodgkin's lymphoma MESHD lymphoma HP, breast and colon cancer HP will enter the study. Patients are randomly assigned to two groups. During two months of treatment, the two groups are treated with either hydroxychloroquine or placebo. Patients will be monitored for COVID-19 symptoms. The primary end point of the study is to investigate the incidence of COVID-19 in patients.Randomisation will be performed using randomly permuted blocks. The allocation ratio in two groups is 1:1. Participants, caregivers, outcome assessor and the data analyst are blinded to group assignment.The calculated total sample size is 60 patients, with 30 patients in each group. The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020. This trial has been registered on the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20200405046958N1.

    Evaluation of COVID 19 infection MESHD in 279 cancer patients treated during a 90-day period in 2020 pandemic

    Authors: Mozaffar Aznab

    doi:10.1101/2020.05.26.20102889 Date: 2020-06-01 Source: medRxiv

    Background: The aim of this study was investigation of COVID-19 disease MESHD and its outcome in cancer patients who needed treatment, in a 90-day period. Methods: Cancer patient who required treatment, were evaluated for potential COVID-19 infection MESHD in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor patients, if they did not have symptoms related to COVID-19, just chest X-ray was requested. If they showed COVID-19 related symptoms, High Resolution CT scan of lungs was requested. For hematology cancer patients, PCR test for COVID-19 infection MESHD was requested as well. Protection measures were considered for personnel of oncology wards. Results: In this study, 279 patients were followed up in this 90-day period. No COVID-19 infection MESHD was observed in 92 cases of breast cancer, 72 cases of colon cancer HP, 14 cases of gastric cancer and 12 cases of pancreaticobiliary cancer .However, in 11 cases of lung cancer, 5 cases brain tumors and 12 cases ovarian cancer; 3 case of COVID-19 were observed. In the hematology cancers group, which included 14 cases of Hodgkin Lymphoma HP Lymphoma MESHD, 23 cases of lymphoproliferative disorder MESHD lymphoproliferative disorder HP, 12 cases of acute leukemia HP leukemia MESHD and 12 cases of multiple myeloma MESHD multiple myeloma HP; three of COVID-19 were observed. Conclusion: Patients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X ray, before the treatment starts

    The Aggressive Surgical Treatment and Outcome of a Colon Cancer HP Patient Infected with SARS-CoV-2 in Wuhan, China and Our Experience Sharing

    Authors: Jinbo Gao; Ming Yang; Lian Liu; Shuang Guo; Yongfeng Li; Chao Cheng

    doi:10.21203/rs.3.rs-23214/v1 Date: 2020-04-16 Source: ResearchSquare

    Background: Cancer patients are at increased risks of novelcoronavirus disease MESHD 2019 (COVID-19). Currently, surgical strategies for cancer patients with COVID-19 are generally suggested to be properly delayed. Case presentation:We presented a 69-year-old Chinese female colon cancer patientwith COVID-19, the first case accepted the surgical treatment during the epidemic season in China. Thepatient developed a fever MESHD fever HP on January 28, 2020. After treatments with Ceftriaxone and Abidol, her fever MESHD fever HP was not reduced yet. A repeat chest computed tomography (CT) scan showed the infectious lesions significantly exacerbated, with a positive result for severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) nucleic acid. An abdomen CT scan indicated the tumor of ascending colon with local wrapped changes. She was diagnosed with ‘Severe novel coronavirus pneumonia’ and ‘Incomplete bowel obstruction: Colon cancer HP?’. After actively anti-inflammatory and anti-viral therapies, aright colectomy with lymph node dissection was performed on March 11. The pathological changes of tissue specimens were further investigated.The patient successfully recovered from COVID-19 and surgery, without any postoperative related complications, and was discharged on the 9th day after operation. No case of surgeon, nurse or anesthetist in our team infected by SARS-CoV-2 occurred. Microscopically, significant degeneration, necrosis MESHD and slough of focal intestinal and colonic mucosal epithelial cells were observed. Conclusions:It is meaningful and imperative to share our experience to protect health care personnel from SARS-CoV-2infection and to provide references for optimizing treatment of cancer patient, at least for the operative intervention absolutely necessary or emergency MESHD surgery,during the outbreak of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.